Foreign contract research companies (CROs) are suspending participating in clinical trials in Russia after the exodus of global drugmakers from the clinical research market in the country earlier this year, reports The Pharma Letter’s local correspondent.
According to the recent report by the Russian Kommersant business paper, in January-November 2023, the share of studies with the involvement of a CRO amounted to 20.5%, which is 4.1 % less than…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
"cros" - Google News
December 20, 2023 at 05:12PM
https://ift.tt/pQHKqtu
Foreign CROs suspending participating in clinical trials in Russia - The Pharma Letter
"cros" - Google News
https://ift.tt/YD06RtZ
https://ift.tt/idKAbSw
Bagikan Berita Ini
0 Response to "Foreign CROs suspending participating in clinical trials in Russia - The Pharma Letter"
Post a Comment